Final answer:
Potential future therapies for Huntington's Disease (HD) include weak glutamate antagonists like memantine or NR2B subunit specific antagonists that can block extrasynaptic NMDA receptors without affecting normal synaptic NMDA receptor activity. These therapies aim to prevent disruptions to mitochondrial membrane potential and cell death.
Step-by-step explanation:
Potential future therapies for Huntington's Disease (HD) include the use of weak glutamate antagonists like memantine or NR2B subunit specific antagonists to block extrasynaptic NMDA receptors without affecting normal synaptic NMDA receptor activity. These drugs may provide a clinically relevant outcome by preventing disruptions to mitochondrial membrane potential and cell death. Research is still ongoing to develop these therapies.